Fallopian Tube News and Research

RSS

New way of growing fallopian tube cells in culture may boost understanding of female genital diseases

A new way of growing fallopian tube cells in culture is expected to give a boost to our understanding and prevention of female gynecological diseases, such as infertility, inflammatory disease, and ovarian cancer.

12 Dec 2015

Opsin proteins contribute to heat-seeking movement of sperm

In their arduous journey to the egg, sperm "feel" the heat of the fallopian tube and "taste" the chemical signals of the ova. But a new Weizmann Institute of Science study published in Scientific Reports, in Nature, shows that sperm actually make quite a bit of use of sensors that have mainly been known to belong to the visual system.

26 Nov 2015

Changes in cellular metabolites regulate earliest stages of embryonic stem cell development

Changes in cellular metabolites have been shown to regulate embryonic stem cell development at the earliest stages of life. Metabolites are simple compounds generated during life-sustaining chemical activities in cells.

17 Nov 2015

Standard clomiphene treatment better than proposed alternative for unexplained fertility

It is estimated that approximately 10 percent of women of child-bearing age may be unable to get pregnant or to carry a pregnancy to term.

26 Sep 2015

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks.

2 Aug 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

No overall survival benefit for bevacizumab in ovarian cancer

Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial.

26 Jun 2015

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Ovarian cancer is notoriously difficult to diagnose and treat, making it an especially fatal disease. Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not normal cells, opening up the possibility that they could be used to diagnose early-stage ovarian cancer.

26 May 2015

Women with ovarian cancer need to be tested for BRCA genes

The genes BRCA1 and BRCA2 play a significant role in hereditary breast and ovarian cancers. Recent media attention has focused on American actress Angelina Jolie's decision to have her ovaries and fallopian tubes surgically removed after genetic testing for such cancers.

16 Apr 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.

25 Mar 2015

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers.

3 Mar 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

2 Mar 2015

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

11 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Researchers reveal mechanism that determines direction of egg flow in fallopian tubes

Researchers in Japan have revealed the mechanism that determines the direction of the transportation of eggs in the fallopian tube.

21 Nov 2014

Genetic testing for breast cancer doubled due to 'Angelina Jolie effect'

In May 2013 Angelina Jolie, who was then Hollywood's highest-paid actress, underwent a double mastectomy after testing positive for a BRCA1 gene mutation that significantly increases the risk of developing breast cancer. A recent study, published by Breast Cancer Research has found that, public knowledge of her decision doubled NHS referrals for genetic testing for breast cancer risk.

19 Sep 2014

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech Inc. today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN® versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

4 Sep 2014

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.

2 Sep 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

New study assesses effectiveness of two surgical treatments for ectopic pregnancy

A new study from Wake Forest Baptist Medical Center looked at pregnancy outcomes in regards to the two surgical treatments for ectopic pregnancy -- salpingectomy, in which the affected fallopian tube is removed, or salpingotomy, in which the tube is preserved.

6 Mar 2014